



PCT/EP200 4 / 0 1 3 7 2 8



INVESTOR IN PEOPLE

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ


RECEIVED	
06 JAN 2005	
WIPO	PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.




Signed

Dated

25 October 2004

Patents Form 1/77

Patents Act 1977
(Rule 16)



1/77
04DEC03 2856950-1 000245
001/7700 0.00-0328040.1

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

4 DEC 2003

The Patent Office

Cardiff Road
Newport
South Wales NP10 8QQ

1. Your reference

PAC/ZOL

2. Patent application number

(The Patent Office will fill in this part)

0328040.1

3. Full name, address and postcode of the or of each applicant
(underline all surnames)

① Robert Edward Coleman, Helen Neville-Webbe ②
③ Ingunn Holen, Catherine Alyson Evans ④

① 08765034001
② 08765059001
③ 08765067001

All the above having the same address:

University of Sheffield
SHEFFIELD S10 2JF

Patent ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

④ 08765075001

4. Title of invention

PHARMACEUTICAL USES OF BISPHOSPHONATES

5. Name of your agent (If you have one)

Craig McLean

"Address for service" in the United Kingdom to which all correspondence should be sent
(including the postcode)

Novartis Pharmaceuticals UK Limited
Patents and Trademarks
Wimblehurst Road
Horsham, West Sussex
RH12 5AB

Patents ADP number (if you know it)

07181522002✓

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day/month/year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier
application

Date of filing
(day/month/year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

No

a) any applicant named in part 3 is not an inventor, or

b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body.

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 15 ✓

Claim(s) 4 ✓

Abstract 1 ✓

Drawing(s)

CF

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*) 1 ✓

Request for substantive examination (*Patents Form 10/77*)


Any other documents
(please specify)

11.

I/We request the grant of a patent on the basis of this application

Signature

Date



Craig McLean

3rd December 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

Mr. Trevor Drew

01403 323069

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

PHARMACEUTICAL USES OF BISPHOSPHONATES

This invention relates to bisphosphonates, in particular to new pharmaceutical uses of, and treatment methods including bisphosphonates.

Bisphosphonates are widely used to inhibit osteoclast activity in a variety of both benign and malignant diseases, which involve excessive or inappropriate bone resorption. These pyrophosphate analogs not only reduce the occurrence of skeletal related events but they also provide patients with clinical benefit and improve survival. Bisphosphonates are able to prevent bone resorption *in vivo*; the therapeutic efficacy of bisphosphonates has been demonstrated in the treatment of osteoporosis, osteopenia, Paget's disease of bone, tumour-induced hypercalcemia (TIH) and, more recently, bone metastases (BM) and multiple myeloma (MM) (for review see Fleisch H 1997 Bisphosphonates clinical. In Bisphosphonates in Bone Disease. From the Laboratory to the Patient. Eds: The Parthenon Publishing Group, New York/London pp 68-163). The mechanisms by which bisphosphonates inhibit bone resorption are still not completely understood and seem to vary according to the bisphosphonates studied. Bisphosphonates have been shown to bind strongly to the hydroxyapatite crystals of bone, to reduce bone turn-over and resorption, to decrease the levels of hydroxyproline or alkaline phosphatase in the blood, and in addition to inhibit the formation, recruitment, activation and the activity of osteoclasts.

Recent studies have also shown that some bisphosphonates may have a direct effect on tumour cells. Thus for example it has been found that relatively high concentrations of bisphosphonates, including zoledronate, induce apoptosis of breast and prostate carcinoma and myeloma cells in vitro (Senaratne et al. Br. J. Cancer, 82: 1459-1468, 2000; Lee et al., Cancer Res., 61: 2602-2608, 2001, Shipman et al. Br. J. Cancer, 98: 665-672 (1997)).

It has now been found that if certain types of bisphosphonates are used in combination with an additional cytotoxic agent to treat cancer cells in vitro, that enhanced, and in some cases synergistic, cell growth inhibition is achieved compared with use of either the

bisphosphonate or cytotoxic agent alone. Suitable cytotoxic agents include taxols or derivatives thereof and TNF-related apoptosis inducing ligand (TRAIL). In particular, the ability of particular combinations of the commonly used chemotherapy agent Paclitaxel (PAC) and the potent anti-resorptive agent Zoledronic acid (ZOL) when administered sequentially, and TRAIL and ZOL when administered sequentially, to induce apoptosis of breast and prostate cancer cells in vitro has now been established. The order in which the agents are given significantly affects the maximum level of apoptosis achieved.

The invention provides a method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of taxol or a derivative thereof followed sequentially by an effective amount of a bisphosphonate.

The invention further provides a method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of a bisphosphonate followed sequentially by an effective amount of TRAIL.

Yet further the invention provides the sequential use of a cytotoxic agent selected from the group consisting of: taxol, a derivative thereof and TRAIL; and a bisphosphonate to inhibit cancer cell growth or induce cancer cell apoptosis.

Accordingly in a yet further aspect the present invention also provides a pharmaceutical preparation for treatment of malignancies, which comprises a cytotoxic agent selected from the group consisting of: taxol, a derivative thereof and TRAIL; and a bisphosphonate for sequential use.

In the present description the term "treatment" includes both prophylactic or preventative treatment as well as curative or disease modifying treatment, including treatment of patients at risk of contracting the disease or suspected to have contracted the disease as well as ill patients.


The invention is generally applicable to the treatment of malignant diseases for which bisphosphonate treatment is indicated. Thus typically the disease is a malignant disease which is associated with the development of bone metastases or excessive bone resorption.

Examples of such diseases include cancers, such as breast and prostate cancers, multiple myeloma (MM), tumour induced hypertension (TIH) and similar diseases and conditions. In particular the invention is applicable to the treatment of bone metastases (BM) associated with cancers such as breast cancer, lung cancer, colon cancer or prostate cancer.

The compositions, uses and methods of the present invention represent an improvement to existing therapy of malignant diseases in which bisphosphonates are used to prevent or inhibit development of bone metastases or excessive bone resorption, and in which (as has been discovered in accordance with the present invention) bisphosphonate treatment also inhibits cancer cell growth or induces cancer cell apoptosis. The sequential use of paclitaxel and a bisphosphonate advantageously gives rise to enhanced, or even synergistic, levels of cancer cell growth inhibition or cancer cell apoptosis.

The bisphosphonates for use in the present invention are preferably N-bisphosphonates.

For the purposes of the present description an N-bisphosphonate is a compound which in addition to the characteristic geminal bisphosphate moiety comprises a nitrogen containing side chain, e.g. a compound of formula I



wherein


X is hydrogen, hydroxyl, amino, alkanoyl, or an amino group substituted by C₁-C₄ alkyl, or alkanoyl;

R is hydrogen or C₁-C₄ alkyl and

Rx is a side chain which contains an optionally substituted amino group, or a nitrogen containing heterocycle (including aromatic nitrogen-containing heterocycles), and pharmaceutically acceptable salts thereof or any hydrate thereof.

Thus, for example, suitable N-bisphosphonates for use in the invention may include the following compounds or a pharmaceutically acceptable salt thereof, or any hydrate thereof: 3-amino-1-hydroxypropane-1,1-diphosphonic acid (pamidronic acid), e.g. pamidronate (APD); 3-(N,N-dimethylamino)-1-hydroxypropane-1,1-diphosphonic acid, e.g. dimethyl-APD; 4-amino-1-hydroxybutane-1,1-diphosphonic acid (alendronic acid), e.g. alendronate; 1-hydroxy-3-(methylpentylamino)-propylidene-bisphosphonic acid, ibandronic acid, e.g. ibandronate; 6-amino-1-hydroxyhexane-1,1-diphosphonic acid, e.g. amino-hexyl-BP; 3-(N-methyl-N-n-pentylamino)-1-hydroxypropane-1,1-diphosphonic acid, e.g. methyl-pentyl-APD (= BM 21.0955); 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid, e.g. zoledronic acid; 1-hydroxy-2-(3-pyridyl)ethane-1,1-diphosphonic acid (risedronic acid), e.g. risedronate, including N-methyl pyridinium salts thereof, for example N-methyl pyridinium iodides such as NE-10244 or NE-10446; 3-[N-(2-phenylthioethyl)-N-methylamino]-1-hydroxypropane-1,1-diphosphonic acid; 1-hydroxy-3-(pyrrolidin-1-yl)propane-1,1-diphosphonic acid, e.g. EB 1053 (Leo); 1-(N-phenylaminothiocarbonyl)methane-1,1-diphosphonic acid, e.g. FR 78844 (Fujisawa); 5-benzoyl-3,4-dihydro-2H-pyrazole-3,3-diphosphonic acid tetraethyl ester, e.g. U-81581 (Upjohn); and 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-diphosphonic acid, e.g. YM 529.

In one embodiment a particularly preferred N-bisphosphonate for use in the invention comprises a compound of Formula II



wherein

Het is an imidazole, oxazole, isoxazole, oxadiazole, thiazole, thiadiazole, pyridine, 1,2,3-triazole, 1,2,4-triazole or benzimidazole radical, which is optionally substituted by alkyl, alkoxy, halogen, hydroxyl, carboxyl, an amino group optionally substituted by alkyl or alkanoyl radicals or a benzyl radical optionally substituted by alkyl, nitro, amino or aminoalkyl;


A is a straight-chained or branched, saturated or unsaturated hydrocarbon moiety containing from 1 to 8 carbon atoms;

X' is a hydrogen atom, optionally substituted by alkanoyl, or an amino group optionally substituted by alkyl or alkanoyl radicals, and

R is a hydrogen atom or an alkyl radical,

and the pharmacologically acceptable salts thereof.

In a further embodiment a particularly preferred bisphosphonate for use in the invention comprises a compound of Formula III



wherein

Het' is a substituted or unsubstituted heteroaromatic five-membered ring selected from the group consisting of imidazolyl, imidazoliny, isoxazolyl, oxazolyl, oxazoliny, thiazolyl, thiazoliny, triazolyl, oxadiazolyl and thiadiazolyl wherein said ring can be

partly hydrogenated and wherein said substituents are selected from at least one of the group consisting of C₁-C₄ alkyl, C₁-C₄ alkoxy, phenyl, cyclohexyl, cyclohexylmethyl, halogen and amino and wherein two adjacent alkyl substituents of Het can together form a second ring;


Y is hydrogen or C₁-C₄ alkyl;

X'' is hydrogen, hydroxyl, amino, or an amino group substituted by C₁-C₄ alkyl, and

R is hydrogen or C₁-C₄ alkyl;

as well as the pharmacologically acceptable salts and isomers thereof.

In a yet further embodiment a particularly preferred bisphosphonate for use in the invention comprises a compound of Formula IV



wherein

Het''' is an imidazolyl, 2H-1,2,3-, 1H-1,2,4- or 4H-1,2,4-triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl or thiadiazolyl radical which is unsubstituted or C-mono- or di-substituted by lower alkyl, by lower alkoxy, by phenyl which may in turn be mono- or disubstituted by lower alkyl, lower alkoxy and/or halogen, by hydroxy, by di-lower alkylamino, by lower alkylthio and/or by halogen and is N-substituted at a substitutable N-atom by lower alkyl or by phenyl-lower alkyl which may in turn be mono- or di-substituted in the phenyl moiety by lower alkyl, lower alkoxy and/or halogen, and

R₂ is hydrogen, hydroxy, amino, lower alkylthio or halogen,

lower radicals having up to and including 7 C-atoms,

or a pharmacologically acceptable salt thereof.

Examples of particularly preferred N-bisphosphonates for use in the invention are:

2-(1-Methylimidazol-2-yl)-1-hydroxyethane-1,1-diphosphonic acid;
2-(1-Benzylimidazol-2-yl)-1-hydroxyethane-1,1-diphosphonic acid;
2-(1-Methylimidazol-4-yl)-1-hydroxyethane-1,1-diphosphonic acid;
1-Amino-2-(1-methylimidazol-4-yl)ethane-1,1-diphosphonic acid;
1-Amino-2-(1-benzylimidazol-4-yl)ethane-1,1-diphosphonic acid;
2-(1-Methylimidazol-2-yl)ethane-1,1-diphosphonic acid;
2-(1-Benzylimidazol-2-yl)ethane-1,1-diphosphonic acid;
2-(Imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid;
2-(Imidazol-1-yl)ethane-1,1-diphosphonic acid;
2-(4H-1,2,4-triazol-4-yl)-1-hydroxyethane-1,1-diphosphonic acid;
2-(Thiazol-2-yl)ethane-1,1-diphosphonic acid;
2-(Imidazol-2-yl)ethane-1,1-diphosphonic acid;
2-(2-Methylimidazol-4(5)-yl)ethane-1,1-diphosphonic acid;
2-(2-Phenylimidazol-4(5)-yl)ethane-1,1-diphosphonic acid;
2-(4,5-Dimethylimidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid, and
2-(2-Methylimidazol-4(5)-yl)-1-hydroxyethane-1,1-diphosphonic acid,
and pharmacologically acceptable salts thereof.

The most preferred N-bisphosphonate for use in the invention is 2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmacologically acceptable salt thereof.

All the N-bisphosphonic acid derivatives mentioned above are well known from the literature. This includes their manufacture (see e.g. EP-A-513760, pp. 13-48). For example, 3-amino-1-hydroxypropane-1,1-diphosphonic acid is prepared as described e.g. in US patent 3,962,432 as well as the disodium salt as in US patents 4,639,338 and 4,711,880, and 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid is prepared as described e.g. in US patent 4,939,130. See also US patents 4,777,163 and 4,687,767.

The N-bisphosphonates may be used in the form of an isomer or of a mixture of isomers where appropriate, typically as optical isomers such as enantiomers or diastereoisomers or geometric isomers, typically cis-trans isomers. The optical isomers are obtained in the form of the pure antipodes and/or as racemates.

The N-bisphosphonates can also be used in the form of their hydrates or include other solvents used for their crystallisation.

Pharmacologically acceptable salts of bisphosphonates are preferably salts with bases, conveniently metal salts derived from groups Ia, Ib, IIa and IIb of the Periodic Table of the Elements, including alkali metal salts, e.g. potassium and especially sodium salts, or alkaline earth metal salts, preferably calcium or magnesium salts, and also ammonium salts with ammonia or organic amines.

Especially preferred pharmaceutically acceptable salts of the N-bisphosphonates are those where one, two, three or four, in particular one or two, of the acidic hydrogens of the bisphosphonic acid are replaced by a pharmaceutically acceptable cation, in particular sodium, potassium or ammonium, in first instance sodium.

A very preferred group of pharmaceutically acceptable salts of the N-bisphosphonates is characterized by having one acidic hydrogen and one pharmaceutically acceptable cation, especially sodium, in each of the phosphonic acid groups.

The N-bisphosphonates are preferably used in the form of pharmaceutical compositions that contain a therapeutically effective amount of active ingredient optionally together with or in admixture with inorganic or organic, solid or liquid, pharmaceutically acceptable carriers which are suitable for administration.

The N-bisphosphonate pharmaceutical compositions may be, for example, compositions for enteral, such as oral, rectal, aerosol inhalation or nasal administration, compositions for

parenteral, such as intravenous or subcutaneous administration, or compositions for transdermal administration (e.g. passive or iontophoretic).

Preferably, the N- bisphosphonate pharmaceutical compositions are adapted to oral or parenteral (especially intravenous, intra-arterial or transdermal) administration. Intravenous and oral, first and foremost intravenous, administration is considered to be of particular importance. Preferably the N-bisphosphonate active ingredient is in a parenteral form, most preferably an intravenous form.

The particular mode of administration and the dosage may be selected by the attending physician taking into account the particulars of the patient, especially age, weight, life style, activity level, and disease state as appropriate. Most preferably, however, the N-bisphosphonate is administered intravenously.

The dosage of the N-bisphosphonate for use in the invention may depend on various factors, such as effectiveness and duration of action of the active ingredient, mode of administration, warm-blooded species, and/or sex, age, weight and individual condition of the warm-blooded animal.

Taxol is the compound [2aR-[2α, 4β, 4αβ, 6β, 9α(αR*, βS*),-11α,12α, 12αα, 12bα]]-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2α,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, alternatively known as Paclitaxel, which is an antileukemic and antitumour agent, first isolated as the l-form from the bark of the Pacific yew tree, *Taxus brevifolia*, *Taxaceae*. Suitable derivatives of taxol for use in the present invention include taxotere (i.e. the compound [2aR-[2α, 4β, 4αβ, 6β, 9α(αR*, βS*),-11α,12α, 12αα, 12bα]]-β-[[[(1,1-dimethylethoxy)carbonyl]-amino]-α-hydroxybenzenepropanoic acid 12b-(acetyloxy)-12-(benzoyloxy) - 2α,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy--4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, alternatively known as

docetaxel), taxanes, taxines (e.g. taxine I, taxine II, taxine A or taxine B) or any other suitable taxol derivative. Taxol and suitable derivatives thereof may be used in combination with a bisphosphonate in the present invention. Paclitaxel (PAC) is a preferred taxol derivative for use in the present invention. The taxol or taxol derivative pharmaceutical composition may be, for example, compositions for enteral, such as oral, rectal, aerosol inhalation or nasal administration, compositions for parenteral, such as intravenous or subcutaneous administration, or compositions for transdermal administration (e.g. passive or iontophoretic).

The Agents of the Invention (a. taxol or derivative thereof or TRAIL and b. the bisphosphonate) are used in the form of separate pharmaceutical preparations that each contain the relevant therapeutically effective amount of the respective active ingredient optionally together with or in admixture with inorganic or organic, solid or liquid, pharmaceutically acceptable carriers which are suitable for administration.

The particular mode of administration and the dosage may be selected by the attending physician taking into account the particulars of the patient, especially age, weight, life style, activity level, etc.

The dosage of the Agents of the Invention may depend on various factors, such as effectiveness and duration of action of the active ingredient, mode of administration, warm-blooded species, and/or sex, age, weight and individual condition of the warm-blooded animal.

The pharmacologically active compounds of the invention are useful in the manufacture of pharmaceutical compositions comprising an effective amount thereof in conjunction or admixture with excipients or carriers suitable for either enteral or parenteral application. Preferred are tablets and gelatin capsules comprising the active ingredient together with a) diluents, e.g. lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine; b) lubricants, e.g. silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for tablets also c) binders e.g. magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and or

polyvinylpyrrolidone; if desired d) disintegrants, e.g. starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or e) absorbents, colorants, flavors and sweeteners. Injectable compositions are preferably aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions. Said compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances. Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1 to 75%, preferably about 1 to 50%, of the active ingredient.

Tablets may be either film coated or enteric coated according to methods known in the art.

Suitable formulations for transdermal application include an effective amount of a compound of the invention with carrier. Advantageous carriers include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host. For example, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.

Suitable formulations for topical application, e.g. to the skin and eyes, include aqueous solutions, suspensions, ointments, creams, gels or sprayable formulations, for example, for delivery by aerosol or the like. Such topical delivery systems will in particular be appropriate for dermal application, e.g. for the treatment of skin cancer, for example, for prophylactic use in creams, lotions sprays and the like.

Other orally administrable pharmaceutical preparations are dry-filled capsules made of gelatin, and also soft, sealed capsules made of gelatin and a plasticiser, such as glycerol or sorbitol. The dry-filled capsules may contain the active ingredient in the form of a granulate, for example in admixture with fillers, such as lactose, binders, such as starches, and/or

glidants, such as talc or magnesium stearate, and, where appropriate, stabilisers. In soft capsules the active ingredient is preferably dissolved or suspended in suitable liquids, such as fatty oils, paraffin oil or liquid polyethylene glycols, it being possible also for stabilisers to be added.

Parenteral formulations are especially injectable fluids that are effective in various manners, such as intravenously, intramuscularly, intraperitoneally, intranasally, intradermally or subcutaneously. Such fluids are preferably isotonic aqueous solutions or suspensions which can be prepared before use, for example from lyophilised preparations which contain the active ingredient alone or together with a pharmaceutically acceptable carrier. The pharmaceutical preparations may be sterilised and/or contain adjuncts, for example preservatives, stabilisers, wetting agents and/or emulsifiers, solubilisers, salts for regulating the osmotic pressure and/or buffers.

Suitable formulations for transdermal application include an effective amount of the active ingredient with carrier. Advantageous carriers include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host. Characteristically, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the active ingredient of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.

The following examples are intended to illustrate the invention and are not to be construed as being limitations thereon.

EXPERIMENTAL

Method 1: PAC and ZOL

MCF7 cells and prostate cancer PC3 cells are seeded and pre-incubated then treated with ZOL and/or PAC in the sequences given below. In the case of the PAC then ZOL sequence, in one of the experiments geranylgerol (GGOH, 50 μ M) is added and then removed with the ZOL. Apoptosis is determined by evaluation of nuclear morphology.

Experiment 1:

Group 1: 25 μ M ZOL (for 1 hour on day 1) followed by 2nM PAC (for 4 hours day 2)

Group 2: 2nM PAC (for 4 hours on day 1) followed by 25 μ M ZOL (for 1 hour on day 2)

Following the last drug exposure the cells in each group are incubated in drug free medium to 48 hours.

Experiment 2:

2nM PAC (for 4 hours on day 1) followed by 1 μ M ZOL (for 1 hour on day 2). Following the last drug exposure the cells are incubated in drug free medium to 48 hours.

Experiment 3:

2nM PAC (for 4 hours on day 1) followed by 25 μ M or 1 μ M ZOL (for 1 hour on day 2), with or without geranylgeraniol (GGOH) 50 μ M (added and removed simultaneously with the ZOL). Following the last drug exposure the cells are incubated in drug free medium to 48 hours.

Results

Experiment 1 results:

Giving 25 μ M ZOL before PAC (Group 1) induces 2.4% apoptosis, whereas maximal induction of apoptosis is seen in cells treated with PAC on day 1 followed by ZOL (25 μ M) on day 2 (Group 2); (6.1%, $p < 0.001$ compared to ZOL or PAC alone).

From these results it is shown that apoptosis is induced in a synergistic fashion but the order of drug exposure is important for maximal apoptosis.

Experiment 2 results:

As is found using higher doses, MCF7 cells treated with PAC (day 1) followed by 1 μ M ZOL (day 2) also induces apoptosis in a synergistic fashion, with 4.1% in the combined group, compared to PAC alone (1.25%, $p=0.004$) and 1 μ M ZOL alone (0.25%, $p=0.004$). These results demonstrate that clinically relevant doses of ZOL are effective at inducing apoptosis. Following infusion of ZOL in vivo peak plasma concentration is 1-2 μ M for a few hours.

Experiment 3 results:

Geranylgeraniol is an intermediary of the mevalonate pathway which is able to reverse the effects of ZOL. Treating MCF7 cells with PAC followed by ZOL combined with geranylgeraniol (GGOH, 50 μ M) prevents the synergistic increase in apoptotic cell death by 70-80%. This shows that ZOL induces apoptosis of MCF7 cells via inhibition of the MVA pathway.

Discussion

Combinations of ZOL and PAC are shown to have a synergistic effect in inducing apoptosis. Additionally, it is found that synergy is achievable with shorter incubation periods and clinically relevant concentrations of ZOL. For maximal induction of apoptosis cells must be exposed to PAC first followed by ZOL, preferably on separate days. Induction of apoptosis is via inhibition of the MVA pathway. Our results suggest that combining PAC and clinically relevant doses of ZOL does induce apoptosis of tumour cells, and that the drug sequence is important for obtaining maximum effect of combined treatment.

Method 2: ZOL and TRAIL

The breast cancer lines MDA-MB-426 and MCF7 and the prostate cancer cell line PC3 are treated with ZOL (25 μ M) and TRAIL (purchased from R&D systems, Abingdon, UK; 10 ng/ml) for varying incubation periods and sequences as follows:

Group 1: TRAIL given first for 24 hours followed by ZOL for 48 hours.

Group 2: ZOL given first for 24 hours followed by TRAIL for 24 hours.

Group 3: ZOL and TRAIL given simultaneously for 24 hours.

Group 4: TRAIL given first for 24 hours then ZOL for 4 hours followed by drug-free medium for 48 hours.

Group 5: ZOL given first for 4 hours and cells maintained in drug-free medium for 48 hours followed by TRAIL for 24 hours.


Results

The combination of ZOL and TRAIL is shown to have synergistic effects in inducing apoptotic death of breast cancer cells, but the order in which the drugs are given is significant. Giving TRAIL before ZOL (group 1) increases apoptosis from 1.75% (TRAIL only) and 0.5% (ZOL only) to 2.4 % in the combined group. Likewise, treating with ZOL and TRAIL together for 24 hours (group 3) increases the level of apoptosis from 1.75% (TRAIL only) and 0.7% (ZOL only) to 2.5% in the combined group. When cells are treated with ZOL for 48 hours followed by TRAIL (group 2), the results indicate synergy between these two drugs. In the combined group there is 14.65% apoptosis which is significantly greater than ZOL only, (0.7% $p < 0.001$) and TRAIL only (2.7% $p < 0.001$). Similar results are obtained when a shorter incubation period with ZOL (4 hours) was used, with apparent synergy obtained only when ZOL is given before TRAIL. Prostate cancer cells are also sensitive to the combination of ZOL and TRAIL when these cells are treated as outlined for group 5.

These results show that the combination of ZOL and TRAIL have a synergistic effect in inducing apoptosis of tumour cells. For maximum effect ZOL has to be given prior to TRAIL treatment.

CLAIMS

1. A pharmaceutical preparation for treatment of malignancies, which comprises a cytotoxic agent selected from the group consisting of: taxol, a derivative thereof and TRAIL; and a bisphosphonate for sequential use.
2. A pharmaceutical preparation according to claim 1 in which the bisphosphonate is an N-bisphosphonate.
3. A pharmaceutical preparation according to claim 1 in which the bisphosphonate is a compound of formula I



wherein


X is hydrogen, hydroxyl, amino, alkanoyl, or an amino group substituted by C₁-C₄ alkyl, or alkanoyl;

R is hydrogen or C₁-C₄ alkyl and

Rx is a side chain which contains an optionally substituted amino group, or a nitrogen containing heterocycle (including aromatic nitrogen-containing heterocycles), or a pharmaceutically acceptable salt thereof or any hydrate thereof.

4. A pharmaceutical preparation according to claim 1, in which the bisphosphonate is 2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmacologically acceptable salt thereof.

5. A pharmaceutical preparation according to claim 1, in which the cytotoxic agent is paclitaxel.
6. A pharmaceutical preparation according to claim 1, in which the cytotoxic agent is TNF-related apoptosis inducing ligand.
7. A method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of taxol or a derivative thereof followed sequentially by an effective amount of a bisphosphonate.
8. A method according to claim 7 wherein the bisphosphonate is an N-bisphosphonate.
9. A method according to claim 7 wherein the bisphosphonate is a compound of formula I



wherein


X is hydrogen, hydroxyl, amino, alkanoyl, or an amino group substituted by C₁-C₄ alkyl, or alkanoyl;

R is hydrogen or C₁-C₄ alkyl and

Rx is a side chain which contains an optionally substituted amino group, or a nitrogen containing heterocycle (including aromatic nitrogen-containing heterocycles), or a pharmaceutically acceptable salt thereof or any hydrate thereof.

10. A method according to claim 7 wherein the bisphosphonate is 2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmacologically acceptable salt thereof.

11. A method according to claim 7 wherein the taxol or derivative thereof is paclitaxel.
12. A method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of a bisphosphonate followed sequentially by an effective amount of TNF-related apoptosis inducing ligand.
13. A method according to claim 12 wherein the bisphosphonate is 2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmacologically acceptable salt thereof.
14. The sequential use of a cytotoxic agent selected from the group consisting of: taxol, a derivative thereof and TRAIL; and a bisphosphonate to inhibit cancer cell growth or induce cancer cell apoptosis.
15. Use according to claim 14 wherein the bisphosphonate is an N-bisphosphonate.
16. Use according to claim 14 wherein the bisphosphonate is a compound of formula I



wherein

X is hydrogen, hydroxyl, amino, alkanoyl, or an amino group substituted by C₁-C₄ alkyl, or alkanoyl;

R is hydrogen or C₁-C₄ alkyl and

Rx is a side chain which contains an optionally substituted amino group, or a nitrogen containing heterocycle (including aromatic nitrogen-containing heterocycles),

or a pharmaceutically acceptable salt thereof or any hydrate thereof.

17. Use according to claim 14 wherein the bisphosphonate is 2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmacologically acceptable salt thereof.
18. Use according to claim 14 wherein the cytotoxic agent is paclitaxel and is delivered prior to the bisphosphonate.
19. Use according to claim 14 wherein the cytotoxic agent is TRAIL and is delivered sequentially after the bisphosphonate.

ABSTRACT**PHARMACEUTICAL USES OF BISPHOSPHONATES**

A method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of taxol or a derivative thereof followed sequentially by an effective amount of a bisphosphonate.

The invention further provides a method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of a bisphosphonate followed sequentially by an effective amount of TRAIL.

4-32199P1/USN - 19-10-01 - PEC

